A5102909265- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Polyomavirus and related diseases
- COVID-19 and healthcare impacts
- Histiocytic Disorders and Treatments
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Cervical Cancer and HPV Research
- Cytomegalovirus and herpesvirus research
- Hepatitis C virus research
- Hereditary Neurological Disorders
- RNA modifications and cancer
- SARS-CoV-2 and COVID-19 Research
- Ferroptosis and cancer prognosis
- Parvovirus B19 Infection Studies
- Chronic Disease Management Strategies
- Bladder and Urothelial Cancer Treatments
- Eosinophilic Disorders and Syndromes
- Lipid metabolism and disorders
- Animal health and immunology
- Hepatocellular Carcinoma Treatment and Prognosis
- Vaccine Coverage and Hesitancy
- Economic and Financial Impacts of Cancer
Imperial College London
2016-2025
Chelsea and Westminster Hospital
2016-2025
Chelsea and Westminster Hospital NHS Foundation Trust
2016
University of Milan
2010
Combination antiretroviral therapy (cART) is standard of care for patients with HIV diagnosed Kaposi's sarcoma (KS), but the current role systemic chemotherapy undefined.Since 1998, a prospective stage-stratified approach has been adopted 469 KS. Patients early-stage (T0) KS are treated cART alone; advanced-stage (T1) receive plus liposomal anthracycline chemotherapy. Clinical characteristics, overall survival, and progression-free survival were analyzed according to stage at presentation...
Abstract Data addressing prognostication in patients with HIV related Burkitt lymphoma (HIV-BL) currently treated remain scarce. We present an international analysis of 249 (United States: 140; United Kingdom: 109) HIV-BL from 2008 to 2019 aiming identify prognostic factors and outcomes. With a median follow up 4.5 years, the 3-year progression-free survival (PFS) overall (OS) were 61% (95% confidence interval [CI] 55% 67%) 66% (95%CI 59% 71%), respectively, similar results both countries....
To compare the outcome of patients diagnosed with HIV infection and diffuse large B-cell lymphoma (DLBCL) treated R-CHOP in cART era that a HIV-negative control group.From 2003 to 2011, 305 (97 HIV-positive) were DLBCL R-CHOP. Clinical features compared using chi-square or Fisher's exact test. Survival analysis was performed Kaplan-Meier method log-rank Multivariate Cox regression proportional hazards model.HIV-positive had more B symptoms extranodal sites disease at diagnosis, but...
The ability to detect and treat pre-malignant anal lesions suggests screening may prevent cancer. incidence of cancer in men who have sex with (MSM) living HIV exceeds that cervical before was introduced.High-resolution anoscopy (HRA) intervention for high-grade squamous intraepithelial (HSILs) offered asymptomatic HIV-positive MSM. Patients HSILs were treated follow-up HRA performed after 6 months, whilst patients low-grade had a repeat 12 months.Three hundred sixty-eight MSM total 1497...
Idiopathic multicentric Castleman disease (iMCD) is a poorly understood hematologic disorder involving cytokine-induced polyclonal lymphoproliferation, systemic inflammation, and potentially fatal multiorgan failure. Although the etiology of iMCD unknown, interleukin-6 (IL-6) an established driver in approximately one-third patients. Anti-IL-6 therapy, siltuximab, only US Food Drug Administration-approved treatment. Few options exist for siltuximab nonresponders, no validated tests are...
Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed validated novel index specific for BL to aid risk stratification, interpretation of trials, targeted development treatment approaches.We derived the International Prognostic Index (BL-IPI) from real-world data set adult patients with treated immunochemotherapy in United States between 2009 2018, identifying candidate variables that showed strongest association progression-free...
<ns4:p>Kaposi sarcoma (KS) is a mesenchymal tumour caused by KS-associated herpesvirus and an AIDS-defining illness. Despite decline in incidence since the introduction of combination anti-retroviral therapy, KS remains most common cancer people living with HIV sub-Saharan Africa, where it causes significant morbidity mortality. This review reflects on recent epidemiological data as well current management, unmet needs future perspectives treatment HIV-associated particular emphasis...
Raltegravir (RAL), an HIV integrase inhibitor, may uncommonly induce increase of serum creatine kinase (CK) both in naïve and antiretroviral (ARV)-experienced HIV-positive patients. We report the case severe rhabdomyolysis requiring hospitalization ARV-experienced HIV/hepatitis C co-infected patient treated with a RAL-containing drug regimen. Factors favouring clinical occurrence RAL-induced from cases reported literature are described.
The aim of the study was to evaluate role plasma Kaposi sarcoma herpesvirus (KSHV) as a diagnostic and prognostic biomarker in people living with HIV (PLWH) diagnosed KSHV-associated diseases.Using quantitative nested polymerase chain reaction (PCR) targeting open reading frame-26 gene KSHV, levels KSHV were measured consecutive PLWH diseases or part investigation lymphadenopathy.Plasma assays performed on samples from 684 20 HIV-seronegative malignancies. In PLWH, detected 39% those KS, 99%...
Introduction: The emergence of combined antiretroviral therapy (cART) and improvements in the management opportunistic infections have altered HIV epidemic over last 30 years. We aimed to assess changes biology outcomes HIV-associated lymphomas this period at national center for oncology United Kingdom. Methods: Clinical characteristics lymphoma diagnosis been prospectively collected since 1986, along with details treatment outcomes. clinical features were compared between 3 decades:...
Large B-cell lymphoma (LBCL) carrying MYC rearrangement, alone or together with BCL2 and/or BCL6 translocations, have shown a poor prognosis when treated rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the HIV population. Scanty data are available on prevalence prognostic impact of rearrangements HIV-associated LBCL. We conducted retrospective study to evaluate clinical effect rearrangement evaluated characteristics, treatment received, outcome LBCL...
The prognosis of non-Hodgkin lymphoma and Hodgkin is not affected by HIV serostatus, yet people living with (PLWH) are frequently excluded from clinical trials in lymphoma.The UK NIHR Clinical Research Network Study Portfolio website was used to identify all the open United Kingdom January 2015. Trials that PLWH were further investigated evaluate if exclusion justified scientific evidence.We identified 56 multicentre including 46 interventional trials. People 32 (70%). We a biologically...
Upregulation of programmed death ligand 1 (PD-L1) is a mechanism immune escape utilized by variety tumors. PD-L1 expression in tumor cells or the surrounding infiltrate correlates with clinical responsiveness to novel therapies targeting PD-1/PD-L1 checkpoint. In context HIV-1 infection, Kaposi's sarcoma (KS) largely responsive restoration immunity following combination antiretroviral therapy (cART), but there subset that not. We hypothesized this cART-refractory KS may utilize pathway...
Highlights This EHA–ESMO Clinical Practice Guideline provides key recommendations for managing HIV‐associated lymphomas. The guideline covers clinical, imaging and pathological diagnosis; staging risk assessment; treatment follow‐up. author group encompasses a multidisciplinary of experts from different institutions countries in Europe. Recommendations are based on available scientific data the authors’ collective expert opinion.
In HIV-seronegative patients with advanced Hodgkin lymphoma (HL), Epstein-Barr virus (EBV) viraemia at diagnosis predicts a worse progression-free survival (PFS), independent of the International Prognostic Score. However, its role in HIV-associated HL is uncharacterised. We collected clinico-pathologic and treatment data from prospective series 44 HLs 2000 to 2016. evaluated circulating EBV DNA as prognostic factor on uni- multivariable analyses relationship Index criteria. HL, was detected...